Orchid Pharma Limited has released its financial results for the quarter and year ended March 31, 2026. The company reported a standalone annual profit of ₹4,520.79 Lakhs. During the year, Orchid Pharma successfully completed the acquisition of Allecra Therapeutics, marking a significant step in repatriating its novel antibiotic, Enmetazobactam. Additionally, the Board has appointed M/s. T R Chadha & Co. LLP as the internal auditor for the upcoming 2026-27 financial year.
Financial Highlights for FY 2025-26
For the financial year ended March 31, 2026, Orchid Pharma posted standalone revenue from operations of ₹81,132.73 Lakhs and a net profit of ₹4,520.79 Lakhs. On a consolidated basis, the company reported total annual revenue of ₹81,132.73 Lakhs and a net profit of ₹2,054.70 Lakhs. The results reflect the company’s performance during a year of strategic consolidation and expansion.
Strategic Acquisitions and Growth
A key milestone for the company in FY 2025-26 was the full acquisition of Allecra Therapeutics GmbH (Germany) and Allecra Therapeutics SAS (France). This acquisition grants Orchid Pharma 100% global ownership of the novel antibiotic molecule Enmetazobactam, commercially known as EXBLIFEP. This move is significant as it consolidates rights and control, facilitating the repatriation of this Indian-discovered molecule back to India.
Internal Governance and Future Outlook
In addition to financial reporting, the company is progressing with the proposed amalgamation of its holding company, Dhanuka Laboratories Limited, with Orchid Pharma. The matter is currently before the National Company Law Tribunal (NCLT), with an order awaiting pronouncement. Furthermore, to strengthen its internal control environment, the Board has appointed M/s. T R Chadha & Co. LLP as the Internal Auditor for the 2026-27 financial year.
Capital Utilization
As of March 31, 2026, the company has utilized ₹33,256 Lakhs of the proceeds raised through its Qualified Institutional Placement (QIP). These funds were primarily directed toward the Jammu Manufacturing Facility and the repayment of outstanding borrowings, underscoring the company’s commitment to expanding its operational capacity and optimizing its debt profile.
Source: BSE
